论文部分内容阅读
目的探究恩替卡韦联合糖皮质激素降阶梯治疗早期乙型重症肝炎的临床疗效。方法将我院收治的早期乙型重症肝炎患者分为对照组和观察组。对照组患者接受恩替卡韦治疗,观察组则在恩替卡韦的基础上进行糖皮质激素的联合治疗。结果观察组ALT、TBIL水平、并发症率、死亡率均低于对照组(P<0.05);与治疗前相比,两组HBV-DNA水平均明显降低(P<0.05)。结论给予患者恩替卡韦联合糖皮质激素联合治疗具有较高的安全性、疗效性,值得推广。
Objective To investigate the clinical efficacy of entecavir plus glucocorticoid descending ladder in the treatment of early severe hepatitis B. Methods The patients with early type B severe hepatitis treated in our hospital were divided into control group and observation group. The control group received entecavir treatment and the observation group received corticosteroid combination therapy based on entecavir. Results The levels of ALT, TBIL, complication rate and mortality in observation group were lower than those in control group (P <0.05). Compared with those before treatment, the levels of HBV-DNA in both groups were significantly decreased (P <0.05). Conclusions The combination of entecavir and glucocorticoid is safe and effective and should be promoted.